ImpediMed

ImpediMed Enterprise Value

The Enterprise Value (EV) of ImpediMed (IPD.AX) as of Sep 28, 2026 is 32.91 M AUD. In the previous year, Enterprise Value (EV) was 23.91 M AUD — a change of 37.65% (higher).

Enterprise Value

32.91 MAUD

YoY

37.65%

Last updated:

Enterprise Value (EV) of ImpediMed is 2026 32.91 M AUD. Enterprise Value (EV) of ImpediMed was 2025 23.91 M AUD. It decreases by 37.65% higher compared to the previous year.

The ImpediMed Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2019
21.14 M AUD
Jan 1, 2020
12.81 M AUD
Jan 1, 2021
12.39 M AUD
Jan 1, 2022
-8.96 M AUD
Jan 1, 2023
-12.66 M AUD
Jan 1, 2024
8.11 M AUD
Jan 1, 2025
23.91 M AUD
Jan 1, 2026
32.91 M AUD
The ImpediMed Enterprise Value history
YEAREnterprise ValueYoY
32.91 MAUD+37.65%
23.91 MAUD+194.75%
8.11 MAUD-164.06%
-12.66 MAUD+41.33%
-8.96 MAUD-172.29%
12.39 MAUD-3.24%
12.81 MAUD-39.42%
21.14 MAUD+4,253.79%
485,590.00AUD-102.09%
-23.23 MAUD-54.08%
-50.58 MAUD+5,053.85%
-981,410.00AUD-104.72%
20.79 MAUD—
Access this data via the Eulerpool API

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Enterprise Value (EV) of ImpediMed is 32.91 M AUD in 2026.

Enterprise Value (EV) of ImpediMed changed from 23.91 M AUD to 32.91 M AUD, representing a 37.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s AUD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' AUD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s ImpediMed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — ImpediMed

All Key Metrics — ImpediMed